Whether furmonertinib has been included in medical insurance and interpretation of medical insurance policies

Furmonertinib (furmonertinib) is a targeted anti-tumor drug independently developed in China. It is mainly used for the treatment of EGFR mutated non-small cell lung cancer. After the drug was approved for marketing by the State Food and Drug Administration, it quickly entered clinical use in China and has been included in the national medical insurance catalog. This undoubtedly reduces the economic pressure on patients and enables more patients to receive standardized targeted therapy.

Under the coverage of medical insurance, the financial burden of fumetinib patients is significantly reduced. According to the latest information, the domestic market price of the drug is about more than 2,000 yuan, which is significantly lower than the out-of-pocket cost when not covered by medical insurance. After payment from medical insurance, the actual out-of-pocket amount of the patient will vary according to the reimbursement ratio in different regions, which makes long-term medication possible and improves patient compliance and treatment continuity.

The medical insurance policy also clearly stipulates the applicable population of fumetinib, mainly for patients with non-small cell lung cancer diagnosed with EGFR mutation-positive patients. When such patients receive targeted therapy, medical insurance can reimburse them according to catalog standards. The reimbursement ratio and limit will vary slightly according to local medical insurance policies. Before purchasing drugs, patients can consult their local hospital or medical insurance department to learn about the specific reimbursement amount and usage process.

It should be noted that even if fumetinib is included in medical insurance, patients still need to strictly follow the doctor's instructions and use the drug according to the prescribed dosage and course of treatment. Rational use of medical insurance drugs can not only ensure the therapeutic effect, but also avoid disease recurrence or drug resistance problems caused by self-adjustment of dosage or arbitrary discontinuation of drugs. In addition, patients should give priority to regular hospital pharmacies or medical insurance designated pharmacies when purchasing medicines to ensure reliable sources of medicines and safe treatment.

Reference materials:https://www.drugs.com/